

**PHASE III TRIAL OF ANTICANCER AGENT LENVIMA®
AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR
CARCINOMA**

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

[Notes to editors]

1. About lenvatinib mesylate (generic name, product name: Lenvima, $\text{L}^{\text{E}}\text{N}^{\text{V}}\text{I}^{\text{N}}\text{I}^{\text{B}}\text{M}^{\text{E}}\text{S}\text{Y}\text{L}\text{A}\text{T}\text{E}$)

Discovered and developed in-house, lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-deri